GE HealthCare Technologies Q3 Earnings Call Highlights

Key Points

• Strong third-quarter results: GE HealthCare’s revenue rose 6.2% organically to $5.5 billion, while adjusted EBIT margin expanded to 16.6%, adjusted EPS increased 25.1% to $1.34, and free cash flow reached $793 million.
• Full-year guidance raised: Management now expects about 4% organic revenue growth, adjusted EPS of $4.95–$5.05, an adjusted EBIT margin of 15.5%–15.7%, and free cash flow above $1.6 billion.
• Pharmaceutical Diagnostics led growth: The segment’s organic revenue increased 13.8%, supported by contrast media and radiopharmaceuticals. The planned SOFIE Biosciences acquisition is expected to strengthen radiopharmaceutical supply and add roughly 1% to annualized company revenue.

GE HealthCare Technologies NASDAQ: GEHC reported third-quarter 2026 revenue growth across all of its business segments, supported by demand in imaging and pharmaceutical diagnostics, improved execution in patient care products and margin expansion.

Revenue totaled $5.5 billion, rising 6.2% organically from a year earlier. Reported product revenue increased 6.7%, while service revenue rose 8.1%. Organic orders grew 4%, producing a book-to-bill ratio of 1.03 times. The company ended the quarter with a $23.7 billion backlog, up $2.5 billion, or 12%, year over year.

Adjusted EBIT margin expanded 180 basis points to 16.6%, while adjusted earnings per share rose 25.1% to $1.34. Free cash flow was $793 million, an increase of $310 million from the prior-year period. GE HealthCare also said it increased its cash dividend by 14%.

Guidance Raised as Execution Improves

CFO Bill Grogan, who recently joined the company, said quarterly performance exceeded expectations on both revenue and profitability. Management raised its full-year 2026 outlook, now forecasting approximately 4% organic revenue growth, adjusted EBIT margin of 15.5% to 15.7%, adjusted EPS of $4.95 to $5.05, and free cash flow above $1.6 billion.

The company expects a foreign-exchange tailwind of about 75 basis points to revenue for the full year and an adjusted effective tax rate of 20% to 21%.

Grogan said margin expansion in the quarter was helped by volume growth, pricing and cost-mitigation actions, along with lower tariff expense than a year earlier. Those gains were partly offset by higher memory-chip costs and the effects of increased oil prices on the supply chain.

CEO Peter Arduini said the company’s “Heartbeat” operating system is supporting commercial and operational simplification, with particular progress in Patient Care Solutions. The segment had faced supplier and fulfillment challenges earlier in the year, but management said daily management processes, standardized work and closer supplier coordination improved product availability during the quarter.

Segment Results Led by Pharmaceutical Diagnostics

• Advanced Imaging Solutions: Organic revenue rose 4.5%, driven by CT, cardiovascular and interventional solutions, and surgical innovations. Segment EBIT margin increased 130 basis points, aided by volume, pricing and reduced tariff expense.
• Pharmaceutical Diagnostics: Organic revenue increased 13.8%, driven by contrast media and radiopharmaceutical products. EBIT margin rose 50 basis points to 29.9%, as volume and pricing more than offset planned investment in new products and innovation.
• Patient Care Solutions: Organic revenue grew 8.8%, supported by improved fulfillment in monitoring solutions and maternal-infant care. Segment EBIT margin expanded 480 basis points, primarily from higher volume and cost productivity.

Management cautioned that Patient Care Solutions will face a difficult fourth-quarter comparison because the segment received an approximately $45 million revenue benefit in the fourth quarter of 2025 from the release of a product hold. Grogan said the company expects fourth-quarter growth of 3% to 4%, with the comparison rather than a market slowdown accounting for the more moderate implied growth rate.

Arduini said installations of monitoring projects that had shifted into the second half are progressing, and the company expects operational improvements in Patient Care Solutions to continue. Jeannette Bankes, the leader of the segment, will leave to become CEO of a non-competitive publicly traded company. Neal Sandy, currently head of product strategy and management for Patient Care Solutions, will succeed her. Arduini said the change will not affect the company’s ongoing evaluation of strategic options for the business.

Radiopharmaceutical Expansion and Product Pipeline

GE HealthCare highlighted Pharmaceutical Diagnostics as a key growth driver, with the segment delivering at least high-single-digit growth for five consecutive quarters. Arduini said about three-quarters of the segment’s portfolio is contrast media, while radiopharmaceuticals represent a faster-growing portion of the business.

The company earlier announced plans to acquire SOFIE Biosciences, which would provide a U.S. “final mile” PET radiopharmaceutical supply footprint. GE HealthCare said SOFIE would add approximately 1% to total company revenue on an annualized basis. In its first full year of ownership, SOFIE is expected to grow revenue in the low double digits and be accretive to adjusted EBIT margin and adjusted EPS.

Arduini said the acquisition would expand supply reliability and deepen the company’s participation in radiopharmaceutical manufacturing and distribution. SOFIE also brings FAPI-74, a phase III PET tracer that GE HealthCare said could support diagnosis and treatment across a range of cancers and other diseases.

The company reported increasing use of its Flyrcado cardiac PET imaging agent, delivering about 680 doses during the week ended Oct. 23. Arduini said adoption has included both existing cardiac PET/CT programs and customers converting from SPECT to PET. Management reaffirmed its expectation that Flyrcado can reach a $500 million revenue run rate exiting 2028.

Supply Chain, China and Capital Equipment Demand

GE HealthCare said it entered multiyear agreements with technology partners to secure supplies of memory chips amid rising demand for advanced computing components. Arduini said the agreements are intended to improve supply predictability and place the company in a favorable position for access to critical components, though he said fixed pricing arrangements may not be practical.

In China, the company said business activity improved sequentially, with growth of 7% in the quarter, though management said most of that increase was driven by foreign exchange. Arduini said tender activity has become more consistent and the company is adjusting product configurations and go-to-market tactics in response to volume-based procurement dynamics.

Management also said its capital-equipment pipeline remains strong. Arduini said imaging equipment continues to rank highly in customer capital-budget priorities, and that the company has not seen a direct slowdown in scan data or contrast-media use. He added that many imaging installations are planned 12 to 24 months in advance, supporting visibility from the company’s backlog into 2027 and beyond.

About GE HealthCare Technologies (NASDAQ:GEHC)

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company's portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.